p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma-Reference-Cited by-同舟云学术

p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma

Published:2021-01 Issue:1 Volume:74 Page:96-108
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Luo Yuan-Deng,Fang Lei,Yu Hong-Qiang,Zhang Jie,Lin Xiao-Tong,Liu Xiao-Yu,Wu Di,Li Gui-Xi,Huang Deng,Zhang Yu-Jun,Chen Shu,Jiang Yan,Shuai Ling,He Yu,Zhang Lei-Da,Bie Ping,Xie Chuan-Ming^ORCID

Funder

Southwest Hospital

Third Military Medical University

Army Medical University

Natural Science Foundation of Chongqing

Publisher

Elsevier BV

Subject

Hepatology

Reference52 articles.

1. The mTOR pathway in hepatic malignancies;Bhat;Hepatology,2013

2. mTOR signaling in growth control and disease;Laplante;Cell,2012

3. Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion;Gupta;PLoS One,2013

4. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size;Saci;Mol Cell,2011

5. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends;Matter;J Hepatol,2014

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capecitabine mitigates cardiac allograft rejection via inhibition of TYMS-Mediated Th1 differentiation in mice;International Immunopharmacology;2024-11

2. Tudor-SN exacerbates pathological vascular remodeling by promoting the polyubiquitination of PTEN via NEDD4-1;Journal of Biomedical Science;2024-09-05

3. Identification of Clinical Value and Biological Effects of XIRP2 Mutation in Hepatocellular Carcinoma;Biology;2024-08-19

4. Lecithin-cholesterol acyltransferase is a potential tumor suppressor and predictive marker for hepatocellular carcinoma metastasis;World Journal of Gastrointestinal Oncology;2024-08-15

5. Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway;Translational Oncology;2024-08